Changes in GOLD: today and tomorrow.

[1]  A. Ramírez-Venegas,et al.  FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. , 2014, American journal of respiratory and critical care medicine.

[2]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[3]  J. Haughney,et al.  The distribution of COPD in UK general practice using the new GOLD classification , 2013, European Respiratory Journal.

[4]  J. Goldberger,et al.  Personalized medicine vs guideline-based medicine. , 2013, JAMA.

[5]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[6]  L. Wood,et al.  Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? , 2013, Thorax.

[7]  P. Jones,et al.  Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification , 2012, European Respiratory Journal.

[8]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[9]  Nicola A Hanania,et al.  Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. , 2011, Radiology.

[10]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[11]  Olaf Holz,et al.  Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. , 2011, Chest.

[12]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[13]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.